Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-29T18:38:44.842Z Has data issue: false hasContentIssue false
  • English
  • Français

C-reactive protein levels and cognitive functions in patients with bipolar disorder

Published online by Cambridge University Press:  19 July 2023

O. Elleuch ,
M. Maalej ,
W. Guidara ,
M. Naifar ,
M. Maalej  and
F. Ayadi
O. Elleuch*
Affiliation:
Department of psychiatry C, Hedi Chaker University Hospital of Sfax
M. Maalej
Affiliation:
Department of psychiatry C, Hedi Chaker University Hospital of Sfax
W. Guidara
Affiliation:
Laboratory of Research “Molecular Basis of HumanDiseases”, LR19ES13, Faculty of Medicine, University of Sfax
M. Naifar
Affiliation:
Laboratory of Research “Molecular Basis of HumanDiseases”, LR19ES13, Faculty of Medicine, University of Sfax
M. Maalej
Affiliation:
Department of psychiatry C, Hedi Chaker University Hospital of Sfax
F. Ayadi
Affiliation:
Laboratory of Research “Molecular Basis of HumanDiseases”, LR19ES13, Faculty of Medicine, University of Sfax Laboratory of Biochemistry, Faculty of Medicine of Sfax & Habib Bourguiba Hospital, Sfax, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The pathophysiology of bipolar disorder (BD) is complex and remains uncertain to this day.

Several hypotheses have been suggested, including the involvement of inflammatory mechanisms in its pathogenesis and in eventual cognitive impairment. C-reactive protein (CRP) is one of the most commonly used inflammatory markers. High-sensitivity CRP (hs- CRP) is a more sensitive marker.

Objectives

We aimed to examine hs-CRP levels in patients with BD, and to investigate its relationship with cognitive functions.

Methods

We conducted a cross-sectional study between June 2016 and July 2018 on drug-free BD patients. These participants were hospitalized at the “C” Psychiatry department of HediChaker University Hospital in Sfax-Tunisia which accepts only male patients. The diagnosis of BP disorder was established according to DSM-5 criteria.

We used the Montreal Cognitive Assessment (MoCA) scale to assess cognitive functions in our patients, and blood samples were collected to analyze hs-CRP levels.

Results

Our study included 33 patients whose median age was 33 years, with an interquartile range of 27.5-44 years. The majority (90.3%) were diagnosed with type I of bipolar disorder and 9.7% were diagnosed with type II. At the time of the study, 82.4% had a maniac episode and 17.6% had a depressive one.

The median MOCA scale score was 24 with an interquartile range of 19-26, and the analysis of hs-CRP values revealed a median level of 2.1 (interquartile range: 1.2-7.3).

There was no significant correlation between hs-CRP levels and MOCA scores nor its domains. Table 1 shows the results of this correlation analysis.Table1:correlation results between hs-CRP levels and MOCA domains

MOCAVisuospatial and executive functionsnamingattentionlanguageabstractionmemoryorientation
hs-CRPr=0.1570.031-0.092-0.0200.0990.0710.055-0.151
p=0.4150.8730.6360.9180.6100.7140.7750.435

We also did not find any significant difference in hs-CRP levels between patients with depressive and maniac episodes.

Conclusions

Our study showed no significant relationship between inflammation and cognitive impairment in bipolar disorder. Further research is needed to better investigate the role of inflammatory processes in this disorder.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S708
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.